鼻内给药醋酸氯脲壳聚糖纳米颗粒治疗阿尔茨海默病

Q2 Pharmacology, Toxicology and Pharmaceutics

Drug Delivery Letters Pub Date : 2023-01-20 DOI:10.2174/2210303113666230120124831

A. Dharamsi, T. Pandya

{"title":"鼻内给药醋酸氯脲壳聚糖纳米颗粒治疗阿尔茨海默病","authors":"A. Dharamsi, T. Pandya","doi":"10.2174/2210303113666230120124831","DOIUrl":null,"url":null,"abstract":"\n\nPresent research work aims to develop Chitosan nanoparticles of leuprolide acetate for intranasal delivery in the treatment of Alzheimer’s disease.\n\n\n\nAlzheimer’s disease (AD) is one of the leading causes and the most prevalent form of age-related dementia worldwide. There is an urgent surge to find an effective treatment for AD due to the social implications it poses on society.\n\n\n\nTo formulate Leuprolide acetate chitosan nanoparticles for intranasal delivery\n\n\n\nChitosan nanoparticles encapsulating leuprolide acetate were prepared using the ionic gelation method and optimized using a central composite design. The optimized nanoparticles were evaluated by DSC study, TEM analysis, in vitro and ex vivo drug release study, histopathology study, and accelerated stability study, In vivo kinetic and dynamic study.\n\n\n\nThe optimized formulation exhibited particle size of 254.3 ± 10.7 nm, \n\n\n\nThus, the chitosan nanoparticulate formulation of leuprolide acetate was found to have great potential for Alzheimer’s disease management.\n\n\n\nNA\n","PeriodicalId":11310,"journal":{"name":"Drug Delivery Letters","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intranasal delivery of leuprolide acetate chitosan nanoparticles for treatment of Alzheimer’s disease\",\"authors\":\"A. Dharamsi, T. Pandya\",\"doi\":\"10.2174/2210303113666230120124831\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nPresent research work aims to develop Chitosan nanoparticles of leuprolide acetate for intranasal delivery in the treatment of Alzheimer’s disease.\\n\\n\\n\\nAlzheimer’s disease (AD) is one of the leading causes and the most prevalent form of age-related dementia worldwide. There is an urgent surge to find an effective treatment for AD due to the social implications it poses on society.\\n\\n\\n\\nTo formulate Leuprolide acetate chitosan nanoparticles for intranasal delivery\\n\\n\\n\\nChitosan nanoparticles encapsulating leuprolide acetate were prepared using the ionic gelation method and optimized using a central composite design. The optimized nanoparticles were evaluated by DSC study, TEM analysis, in vitro and ex vivo drug release study, histopathology study, and accelerated stability study, In vivo kinetic and dynamic study.\\n\\n\\n\\nThe optimized formulation exhibited particle size of 254.3 ± 10.7 nm, \\n\\n\\n\\nThus, the chitosan nanoparticulate formulation of leuprolide acetate was found to have great potential for Alzheimer’s disease management.\\n\\n\\n\\nNA\\n\",\"PeriodicalId\":11310,\"journal\":{\"name\":\"Drug Delivery Letters\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Delivery Letters\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2210303113666230120124831\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2210303113666230120124831","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

本研究的目的是研制醋酸leuprolide壳聚糖纳米颗粒，用于鼻内给药治疗阿尔茨海默病。阿尔茨海默病(AD)是世界范围内与年龄相关的痴呆症的主要原因之一和最普遍的形式。由于阿尔茨海默病对社会造成的影响，迫切需要找到一种有效的治疗方法。采用离子凝胶法制备了包封醋酸良良酯的壳聚糖纳米颗粒，并采用中心复合设计对其进行了优化。通过DSC研究、TEM分析、体外离体药物释放研究、组织病理学研究、加速稳定性研究、体内动力学和动力学研究对优化后的纳米颗粒进行了评价。优化后的制剂粒径为254.3±10.7 nm，表明壳聚糖纳米粒制剂在治疗阿尔茨海默病方面具有很大的潜力。NA

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intranasal delivery of leuprolide acetate chitosan nanoparticles for treatment of Alzheimer’s disease

Present research work aims to develop Chitosan nanoparticles of leuprolide acetate for intranasal delivery in the treatment of Alzheimer’s disease. Alzheimer’s disease (AD) is one of the leading causes and the most prevalent form of age-related dementia worldwide. There is an urgent surge to find an effective treatment for AD due to the social implications it poses on society. To formulate Leuprolide acetate chitosan nanoparticles for intranasal delivery Chitosan nanoparticles encapsulating leuprolide acetate were prepared using the ionic gelation method and optimized using a central composite design. The optimized nanoparticles were evaluated by DSC study, TEM analysis, in vitro and ex vivo drug release study, histopathology study, and accelerated stability study, In vivo kinetic and dynamic study. The optimized formulation exhibited particle size of 254.3 ± 10.7 nm, Thus, the chitosan nanoparticulate formulation of leuprolide acetate was found to have great potential for Alzheimer’s disease management. NA

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drug Delivery Letters Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

1.70

自引率

0.00%

发文量